Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora was noninferior to once-daily degludec in reducing glycated hemoglobin levels. (Funded by Eli Lilly; QWINT-2 ClinicalTrials.gov number, NCT05362058.).
Authors
- Stefano Del Prato (ORCID: https://orcid.org/0000-0002-5388-0270)
- Carol Wysham (ORCID: https://orcid.org/0000-0002-3056-0047)
- Denise Reis Franco (ORCID: https://orcid.org/0000-0003-4961-0638)
- Harpreet S. Bajaj (ORCID: https://orcid.org/0000-0002-1461-1465)
- Arihiro Kiyosue
- Chunmei Zhou
- Molly C. Carr
- Dominik Dahl
- Michael Case
- LIVIA FIRMINO GONCALVES
Institutions
- Scuola Superiore Sant'Anna (IT)
- Eli Lilly (United States) (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Praxis für Humangenetik (DE)
- Rockwood Clinic (US)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1056/nejmoa2403953
- Citations
- 42
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 15.02
Funders
- Eli Lilly and Company